𝔖 Bobbio Scriptorium
✦   LIBER   ✦

ChemInform Abstract: Muscarinic Agonists and Antagonists in the Treatment of Alzheimer′s Disease

✍ Scribed by W. Greenlee; et al. et al.

Publisher
John Wiley and Sons
Year
2010
Weight
24 KB
Volume
32
Category
Article
ISSN
0931-7597

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Xanomeline: A selective muscarinic agoni
Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease
✍ Frank P. Bymaster; Celia A. Whitesitt; Harlan E. Shannon; Neil DeLapp; John S. W 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 2 views

Xanomeline is a novel muscarinic receptor agonist relatively devoid of parasympathomimetic side effects. Xanomeline had high affinity for muscarinic receptors and much lower affinity for a variety of other neuronal receptors in radioligand binding assays. Functional studies in cell lines transfected

WAL 2014 FU (talsaclidine): A preferenti
WAL 2014 FU (talsaclidine): A preferentially neuron activating muscarinic agonist for the treatment of Alzheimer's disease
✍ Helmut A. Ensinger; Wolf-Dieter Bechtel; Franz W. Birke; Klaus D. Mendla; Joachi 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB 👁 2 views

The functional selectivity of WAL 2014 FU with regard to stimulation of the neuronal muscarinic M 1 receptor subtype in vitro and in vivo is shown in different receptor preparations, isolated organ models, whole animal testing, and finally humans. From receptor binding experiments in membrane prepar

Advances in the drug treatment of Alzhei
Advances in the drug treatment of Alzheimer's Disease
✍ B. E. Leonard 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB 👁 2 views

There are two main approaches to the treatment of Alzheimer's disease. The ®rst approach is to prevent the neurodegenerative changes that ultimately cause irreversible damage to the brain. As the excessive formation of betaamyloid protein appears to play a primary role in the neurodegenerative proce